June 6, 2017 08:56 AM EDT
Pharma

AM­RI fetch­es $922M in the lat­est CRO pri­vate eq­ui­ty buy­out

John Carroll

Editor & Founder

There’s an­oth­er pri­vate eq­ui­ty deal to re­port on from the CRO front.

Al­bany, NY-based AM­RI $AM­RI an­nounced Tues­day morn­ing that it is be­ing bought out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Sanofi’s Kymab-orig­i­nat­ed in­flam­ma­to­ry drug flunks mid-stage asth­ma tri­al

Ex­clu­sive: A small biotech will bring Roche's An­gel­man drug back to life

Mur­al On­col­o­gy ends clin­i­cal de­vel­op­ment, lays off most work­ers

Sid­dhartha Mukher­jee’s cell ther­a­py start­up nar­rows fo­cus as staff shrinks

Mer­ck ex­plores po­ten­tial of oral pep­tides in deal with Aus­tri­an biotech

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times